Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...

Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

In a report released today, Harry Gillis from Berenberg Bank upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $130.00. The company’s shares closed yesterday at $101.87.

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...

BioNTech (BNTX) is up more than +2% after Berenberg initiated coverage on the stock with a buy recommendation and a price target of $130. Amer Sports Inc (AS), AZEK Co Inc/The (AZEK), Dolby ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

US stock futures fell Tuesday, weighed by heightened geopolitical tensions after Russian President Vladimir Putin issued a ...

Shares of BioNTech stock opened at $99.72 on Thursday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ...